Source comparison
Thymosin Alpha-1 Beginners Guide: Protocol Comparison
Different research contexts require tailored approaches to Thymosin Alpha-1 administration. The table below compares standard protocols across the three most common experimental applications. Viral Infection Models (Hepatitis, Influenza) 1.6 mg per injection (
This comparison does not assign a generated winner or score.
- Different research contexts require tailored approaches to Thymosin Alpha-1 administration. The table below compares standard protocols across the three most common experimental applications.
- Viral Infection Models (Hepatitis, Influenza)
- 1.6 mg per injection (human equivalent); 100–200 mcg/kg (murine)
- Twice weekly (subcutaneous)
- 12–24 weeks
- Viral load reduction, seroconversion rates, CD4+/CD8+ ratios, IFN-gamma levels
- Best for studies requiring sustained immune activation with measurable viral clearance as the outcome
- Cancer Immunotherapy (Melanoma, NSCLC)
- 1.6–3.2 mg per injection (human equivalent); 200–400 mcg/kg (murine)
- Twice weekly (subcutaneous), often combined with checkpoint inhibitors
- 8–16 weeks
- Tumor volume, tumor-infiltrating lymphocyte density, PD-L1 expression, overall survival
- Most effective when combined with anti-PD-1 or anti-CTLA-4 agents; monotherapy shows limited efficacy
- Immune Reconstitution (Post-Chemotherapy, HIV)
- 1.6 mg per injection (human equivalent); 100–300 mcg/kg (murine)
- 8–12 weeks
- Absolute lymphocyte count, thymic output markers (CD31+ recent thymic emigrants), IL-2 production
- Requires functional thymic tissue; ineffective in complete thymic atrophy models
- The reconstitution concentration affects injection volume and subject tolerability. Most researchers prepare 2 mg Thymosin Alpha-1 in 2 mL bacteriostatic water (1 mg/mL concentration) for murine studies, allowing precise dosing with standard insulin syringes. Human-equivalent protocols often use 1.6 mg per 1 mL, delivering the full dose in a single subcutaneous injection.